Allurion Technologies Files S-1/A Amendment
Ticker: ALURW · Form: S-1/A · Filed: Sep 30, 2024 · CIK: 1964979
Sentiment: neutral
Topics: amendment, financials, medical-devices
TL;DR
Allurion Tech S-1/A filed 9/30, retroactively adjusted shares post-biz combo. Watch closely.
AI Summary
Allurion Technologies, Inc. filed an S-1/A amendment on September 30, 2024, detailing its financial status and business operations. The company, previously known as Allurion Technologies Holdings, Inc., is involved in the surgical and medical instruments sector. The filing indicates a retrospective adjustment to common shares and net loss per share calculations due to a business combination, affecting periods prior to this event.
Why It Matters
This filing provides updated financial information and disclosures for Allurion Technologies, Inc., which is crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — The retrospective adjustment of share counts and net loss per share due to a business combination introduces complexity and potential uncertainty for investors.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
- 20230207 — Date of Name Change (Marks the official change from Allurion Technologies Holdings, Inc. to Allurion Technologies, Inc.)
Key Players & Entities
- ALLURION TECHNOLOGIES, INC. (company) — Filer name
- ALLURION TECHNOLOGIES HOLDINGS, INC. (company) — Former company name
- 20240930 (date) — Filing date
- 333-279902 (dollar_amount) — SEC file number
- 0001964979 (dollar_amount) — Central Index Key
FAQ
What was the specific reason for the retrospective adjustment of common shares and net loss per share?
The filing states that the weighted-average common shares and net loss per share calculations were retrospectively adjusted to the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse capitalization.
When was the company formerly known as Allurion Technologies Holdings, Inc.?
The company's name was changed from Allurion Technologies Holdings, Inc. on February 7, 2023.
What is Allurion Technologies, Inc.'s primary industry classification?
Allurion Technologies, Inc. is classified under 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' with the SIC code [3841].
What is the filing date of this S-1/A amendment?
The S-1/A filing was made on September 30, 2024.
Where is Allurion Technologies, Inc. headquartered?
The company's business address is 11 Huron Dr Ste 200, Natick, MA 01760.
Filing Stats: 4,656 words · 19 min read · ~16 pages · Grade level 14.8 · Accepted 2024-09-30 16:53:22
Key Financial Figures
- $0.0001 — 1,325 shares of common stock, par value $0.0001 per share ("common stock"), of Allurion
- $0.62 — ommon stock as reported on the NYSE was $0.62 per share. Sales of a substantial num
- $4.0 million — op Purchasers purchased an aggregate of $4.0 million of the HVL Bridge Note at the Backstop
- $28.7 million — or " 2023 Convertible Notes " refers to $28.7 million aggregate principal amount of convertib
- $100.0 million — agreed to purchase from Allurion up to $100.0 million of freely tradable shares of common sto
- $11 — A Common Stock at an exercise price of $11.50, subject to adjustment as set forth
- $60 million — refers to the term loan in an amount of $60 million provided by Fortress to Legacy Allurion
- $13 million — VL Bridge Note " refers to that certain $13 million Bridge Note sold to HVL on February 15,
Filing Documents
- d837986ds1a.htm (S-1/A) — 4933KB
- d837986dex231.htm (EX-23.1) — 1KB
- d837986dexfilingfees.htm (EX-FILING FEES) — 32KB
- g837986g30a01.jpg (GRAPHIC) — 37KB
- g837986g30a02.jpg (GRAPHIC) — 116KB
- g837986g30a03.jpg (GRAPHIC) — 63KB
- g837986g30a04.jpg (GRAPHIC) — 141KB
- g837986g30a05.jpg (GRAPHIC) — 158KB
- g837986g30a06.jpg (GRAPHIC) — 89KB
- g837986g30a07.jpg (GRAPHIC) — 165KB
- g837986g30a08.jpg (GRAPHIC) — 43KB
- 0001193125-24-229059.txt ( ) — 22162KB
- alur-20240830.xsd (EX-101.SCH) — 116KB
- alur-20240830_cal.xml (EX-101.CAL) — 74KB
- alur-20240830_def.xml (EX-101.DEF) — 570KB
- alur-20240830_lab.xml (EX-101.LAB) — 807KB
- alur-20240830_pre.xml (EX-101.PRE) — 732KB
- d837986ds1a_htm.xml (XML) — 4537KB
RISK FACTORS
RISK FACTORS 23 PRIVATE PLACEMENTS 80
USE OF PROCEEDS
USE OF PROCEEDS 82 DETERMINATION OF OFFERING PRICE 83 MARKET PRICE AND DIVIDEND INFORMATION 84
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 111 MANAGEMENT 135
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 146 DIRECTOR COMPENSATION 151 PRINCIPAL STOCKHOLDERS 153 SELLING SECURITYHOLDER 155 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 158
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 163 SECURITIES ACT RESTRICTIONS ON RESALE OF OUR SECURITIES 176 PLAN OF DISTRIBUTION 177 LEGAL MATTERS 179 EXPERTS 179 WHERE YOU CAN FIND MORE INFORMATION 179 INDEX TO FINANCIAL STATEMENTS ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES F-1 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (dollars in thousands) F-3 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands, except per share amounts) F-4 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (dollars in thousands) F-5 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (dollars in thousands) F-6 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) F-7 ALLURION TECHNOLOGIES, INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (dollars in thousands, except per share amounts) F-8 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC whereby the selling securityholder may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale by such selling securityholder of the securities offered by it described in this prospectus. Neither we nor the selling securityholder has authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholder takes responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholder will make an offer to